Navigation Links
Novalung Records 50% Growth

ANN ARBOR, Mich., March 23 /PRNewswire/ -- The innovative therapies for lung failure from medical device company Novalung GmbH continue to gain acceptance.  Additional financing will allow the Talheim (Germany) based company to accelerate the development of new products.

Novalung GmbH increased sales by 50% in 2009.  The increasing acceptance of the company's innovative therapies for lung failure both in Germany and abroad is driving continuing growth. Manufacturing operations moved into a new, larger clean-room facility at the end of 2009.

In order to maintain this growth and to fund further international expansion, the private equity group Zukunftsfonds Heilbronn GmbH & Co.KG ("Future Fund of Heilbronn", zfhn) and the LBank, state bank of Baden-Wurttemberg, completed an additional financing round for Novalung. The zfhn acted as lead investor for the second time.

Thanks to the additional funding, commercialization of new products can be pursued more aggressively. These measures put Novalung in an excellent position to establish itself internationally as the pioneering provider of solutions for lung failure, and to revolutionize the treatment of lung failure with new therapies.

Novalung products allow a paradigm shift from the mechanically ventilated patient in an artificial coma to the awake, mobile patient breathing spontaneously. The innovative technologies to replace mechanical ventilation and eliminate the associated ventilator-induced lung injury advance this approach and provide physicians, nurses and patients with new therapeutic options.

Novalung's vision for the future for the long-term treatment of patients with advanced lung disease is a small, wearable artificial lung that frees patients from respiratory stress, improves their overall condition and thus improves their quality of life.

Founded in 2003, Novalung GmbH operates on a highly international level in order to establish new solutions for lung failure. These advanced technologies from Germany and the U.S. were brought into the company and developed further.  Novalung's devices have been used to treat more than 5,000 patients.

The privately funded Novalung GmbH is a fast growing medical technology company based in the area of Heilbronn, Germany, with a subsidiary in Ann Arbor, Michigan.

Novalung has received limited FDA clearance to market its devices in the U.S., and the company plans to begin clinical trials here in 2010 to expand its indications in extracorporeal lung support.

SOURCE Novalung, Inc.

Back to top



SOURCE Novalung, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Praxis Electronic Medical Records Announces New Version 5 With Breakthrough in EHR Documentation
2. Aprima and MednetwoRx Partner to Provide Electronic Health Records and Remote Hosting Option to Physician Practices
3. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
4. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
5. NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference
6. Vermillion to Present at the Roth 22nd Annual OC Growth Stock Conference March 15 - 17, Laguna Niguel, CA
7. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
8. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
9. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
10. DUSA Pharmaceuticals to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference
11. Acuo Technologies Announces Another Significant Sales and Implementation Growth Year
Post Your Comments:
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):